Advertisement
Advertisement
GSK
GSK plc - ADR
50.41
USDSponsored
-0.04
-0.08%
Nov 16, 16:00 UTC -5
Closed
After-Market
50.25
-0.16
-0.31%
GSK plc - ADR (GSK) Earnings
GSK Earnings Reports
Positive Surprise Ratio
GSK beat 36 of 43 last estimates.
84%
Next Report
Date of Next Report
Feb 03, 2027
Estimate for Q4 26 (Revenue/ EPS)
$9.10B
/$0.29
Implied change from Q3 26 (Revenue/ EPS)
+2.39%
/-46.30%
Implied change from Q4 25 (Revenue/ EPS)
+5.59%
/+16.00%
GSK plc - ADR earnings per share and revenue
On Oct 28, 2026, GSK reported earnings of 0.54 USD per share (EPS) for Q3 26, beating the estimate of 0.52 USD, resulting in a 3.51% surprise. Revenue reached 8.89 billion, compared to an expected 9.09 billion, with a -2.18% difference. The market reacted with a -4.32% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 0.29 USD, with revenue projected to reach 9.10 billion USD, implying an decrease of -46.30% EPS, and increase of 2.39% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

ALX Oncology Holdings Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.15
Surprise
-6.31%

Genelux Corporation Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.22%

Neumora Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.20
Actual
-$0.18
Surprise
+10.54%

Eloxx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.58
Actual
-$0.49
Surprise
+16.70%

Rein Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%

LeonaBio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.73
Actual
-$0.89
Surprise
-20.35%

Estrella Immunopharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.17
Surprise
-108.33%

Jasper Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.02
Actual
-$13.97
Surprise
-361.93%

Kyntra Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.61
Actual
-$3.42
Surprise
+5.49%

CNS Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.24
Surprise
+12.85%
FAQ
What were GSK plc - ADR's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, GSK plc - ADR reported EPS of $0.54, beating estimates by 3.51%, and revenue of $8.89B, -2.18% below expectations.
How did the market react to GSK plc - ADR's Q3 2026 earnings?
The stock price moved down -4.32%, changed from $50.94 before the earnings release to $48.74 the day after.
When is GSK plc - ADR expected to report next?
The next earning report is scheduled for Feb 03, 2027.
What are the forecasts for GSK plc - ADR's next earnings report?
Based on --
analysts, GSK plc - ADR is expected to report EPS of $0.29 and revenue of $9.10B for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.